Brookline analyst Kemp Dolliver initiated coverage of electroCore with a Buy rating and $1.25 price target. GammaCore Sapphire, a non-invasive vagus nerve stimulation device that is FDA approved, "brings a new technique for an old treatment," said Dolliver.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ECOR:
- electroCore launches new wellness product called Truvaga
- electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
- electroCore announces issuance of two new U.S. patents
- electroCore Announces Issuance of Two New U.S. Patents
- gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association